The global market for connected insulin pens could be worth up to $123 million by 2023, according to a report published this year by Research & Markets. Insulin pens, designed for people who control their diabetes with multiple daily injections instead of a pump or wearable patch, are portable devices that were first introduced in 1985 with […]
Pharmaceuticals
Q Biomed seeks FDA nod for new manufacturing facility
Q Biomed (OTC:QBIO) and Bio-Nucleonics, the company licensing Q Biomed’s strontium chloride injection, have asked the FDA to approval a new manufacturing facility for the drug. Strontium-89 is a non-opioid injectable designed to relieve pain in patients with metastatic bone disease. The drug is given in a single injection and takes two weeks to reach its […]
Bellerophon Therapeutics misses EPS estimates in Q4
Shares in Bellerophon Therapeutics (NSDQ:BLPH) fell slightly today after the company missed earnings expectations on Wall Street with its fourth-quarter and full-year results. The Warren, N.J.-based company posted a net loss of -$24.2 million, or -44¢ per share, for the 3 months ended Dec. 31. The company’s bottom-line losses grew -227% compared with the same period […]
Report: Senators take aim at pharmacy “gag clauses”
A bipartisan group of senators introduced two bills this week to stop “gag clauses” – conditions that prevent pharmacists from telling customers when they could save money on a prescription if they paid out of pocket rather than using insurance. These clauses are sometimes included in the contracts inked between the various parties that dictate […]
Organogenesis launches new sizing option for PuraPly wound care device
MIT-spinoff Organogenesis announced today that its PuraPly antimicrobial wound care device is now available in a 1.6-cm disc size. The Canton, Mass.-based company’s PuraPly AM product includes a broad-spectrum antibiotic, polyhexamethylene biguanide, embedded into a purified native collagen matrix. The device is cleared to treat an array of wound types, including pressure ulcers, surgical wounds, trauma wounds […]
MIT study reveals the problem with bioresorbable stents
Bioresorbable coronary scaffolds, designed to avoid the risks associated with the long-term implantation of metal stents, once captured the attention of medtech giants like Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX). But companies have since linked the use of these biodegradable polymer-based devices to a heightened risk of myocardial infarction and thrombosis, prompting Abbott to pull its Absorb […]
Inovio Pharmaceuticals logs Q4 earnings, sales beat
Inovio Pharmaceuticals (NSDQ:INO) topped sales and earnings estimates on Wall Street yesterday with its fourth quarter and full year results. The Plymouth Meeting, Pa.-based company posted a net loss of -$21.5 million on sales of $8.8 million for the 3 months ended Dec. 31, for bottom-line growth of 17.9% on sales growth of 3.5% compared with […]
Glooko touts patient outcomes for remote diabetes care tech
Glooko touted data today from a six-month pilot program that evaluated the company’s remote diabetes management technology for people with Type II diabetes. The pilot, which spanned from April until October of 2016, involved 50 Type II diabetes patients from San Diego, Calif.-based Sharp Rees-Stealy Medical Group. The medical group evaluated patient engagement, A1c levels, […]
Clearside Biomedical posts Street-beating Q4, full year results
Shares in Clearside Biomedical (NSDQ:CLSD) fell today even though the biopharmaceutical company topped sales and earnings estimates on Wall Street with its fourth quarter and full year results. The Alpharetta, Ga.-based company posted a net loss of -$16.5 million on sales of $55,000 for the three months ended Dec. 31, for bottom-line loss of -70% on […]
Controversial “right to try” bill fails in the House
A controversial bill that would grant terminal patients access to experimental therapies failed yesterday in the House. Although the “right to try” effort didn’t muster up enough votes to send it to the Senate, majority leader Rep. Kevin McCarthy (R-CA) said in a statement that the fight wasn’t over. “We will try again, pass legislation, […]